Effects of pemafibrate on saccharometabolism in patients with hypertriglyceridemia complicated with diabetes

INTERVENTION: Group A: In addition to dietary therapy for 12 weeks, oral administration of 0.2 mg pemafibrate in the morning and evening Group B: 12week dietary therapy CONDITION: Diabetes PRIMARY OUTCOME: Change in blood glucose level AUC0‐2h by 75g OGTT from baseline to 12 weeks (parallel group) SECONDARY OUTCOME: ‐ Changes of various parameters from baseline to the 12th week by 75g OGTT (before / after / parallel group); ‐ Changes of various parameters from baseline to the (4)12th week (before / after / parallel group); ‐ Percentage of transition from borderline to diabetic or normal, diabetic to borderline or normal; ‐ Occurrence of adverse events and diseases INCLUSION CRITERIA: 1. Fasting triglycerides over 150mg/dL and less than 500 mg / dL (values for 12 weeks prior participation can be adopted) 2. Agreed to receive 75g OGTT 3. Aged 20‐75 on day of signing informed consent 4. Patients who have received sufficient explanation for participation in this study, and who have fully understood the study plan and consented to the document by their own will